---
provider: perplexity
model: sonar-pro
cached: false
start_time: '2025-11-03T22:14:26.256847'
end_time: '2025-11-03T22:14:43.282261'
duration_seconds: 17.03
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    reasoning_effort: low
    search_domain_filter: []
    return_citations: true
    temperature: 0.0
citation_count: 13
---

## Question

Research the SGCA (Q16586) gene in human, focusing on its molecular function, biological processes, and cellular localization. Include information about protein domains, known interactions, and any disease associations.

## Output

## SGCA (Q16586) Gene: Comprehensive Research Report

### Key Concepts and Definitions

**SGCA** (Sarcoglycan Alpha) is a protein-coding gene in humans that encodes alpha-sarcoglycan, a critical component of the dystrophin-glycoprotein complex (DGC)[1][3][11]. The DGC is a transmembrane protein complex essential for maintaining the structural integrity of muscle fiber membranes by linking the intracellular actin cytoskeleton to the extracellular matrix[1][3][11]. This linkage is vital for muscle cell stability during contraction and relaxation cycles.

**Molecular Function:**  
Alpha-sarcoglycan, the protein product of SGCA, is part of the sarcoglycan subcomplex within the DGC. It contributes to the mechanical stability of the sarcolemma (muscle cell membrane) and is implicated in calcium ion binding, which may play a role in muscle signaling[1][10]. The gene is expressed almost exclusively in striated (skeletal and cardiac) muscle[1].

**Biological Processes:**  
SGCA is involved in muscle organ development, skeletal muscle tissue regeneration, muscle contraction, and response to denervation[10]. Its primary role is to stabilize the muscle membrane and protect muscle fibers from damage during mechanical stress[1][3][11].

**Cellular Localization:**  
Alpha-sarcoglycan localizes to the sarcolemma, specifically within the dystrophin-associated glycoprotein complex and membrane rafts[10]. It is also found at cell-cell junctions and in the cytoplasm, reflecting its role in membrane-cytoskeleton linkage[10].

**Protein Domains:**  
While detailed domain architecture is not fully elucidated in the primary literature, alpha-sarcoglycan is a single-pass transmembrane protein with extracellular, transmembrane, and cytoplasmic regions. It is known to interact with other sarcoglycans (beta, gamma, delta) to form the sarcoglycan complex[1][3][11].

**Known Interactions:**  
SGCA interacts with biglycan, a proteoglycan involved in extracellular matrix organization[3]. It also forms essential interactions within the DGC, particularly with dystrophin, syntrophins, and dystroglycans[3]. These interactions are crucial for the structural and functional integrity of muscle fibers.

**Disease Associations:**  
Mutations in SGCA cause autosomal recessive limb-girdle muscular dystrophy type 2D (LGMDR3), also known as sarcoglycanopathy[1][3][4]. This condition is characterized by progressive muscle wasting, typically beginning in childhood, and often leads to loss of ambulation in adolescence[3][4]. The disease is part of a broader group of muscular dystrophies linked to DGC dysfunction.

### Recent Developments and Latest Research (2023–2024)

**Gene Editing and Therapeutic Approaches:**  
Recent studies have demonstrated the potential of base editing to repair SGCA mutations in human primary muscle stem cells, offering a promising avenue for gene therapy in sarcoglycanopathies[5][12]. This approach aims to correct the underlying genetic defect and restore normal protein function, potentially halting or reversing disease progression.

**Functional Genomics:**  
Ongoing research continues to refine the understanding of SGCA’s role within the DGC and its contribution to muscle membrane stability. Advances in proteomics and glycomics are providing deeper insights into post-translational modifications and interactions of alpha-sarcoglycan[10].

**Disease Mechanisms:**  
Studies emphasize that SGCA mutations disrupt the sarcoglycan complex, leading to sarcolemma instability, increased susceptibility to mechanical stress, and eventual muscle fiber necrosis[1][3]. The exact mechanisms by which calcium ion binding by alpha-sarcoglycan contributes to pathology remain an active area of investigation[1][10].

### Current Applications and Real-World Implementations

**Diagnostics:**  
Genetic testing for SGCA mutations is a standard part of the diagnostic workup for patients with limb-girdle muscular dystrophy, especially in cases with autosomal recessive inheritance[1][4]. Identification of specific mutations can guide genetic counseling and inform prognosis.

**Therapeutic Development:**  
Gene therapy trials targeting SGCA and other sarcoglycan genes are in preclinical and early clinical phases. Base editing and CRISPR/Cas9 technologies are being explored to correct mutations in patient-derived cells, with the goal of advancing toward clinical trials[5][12]. These approaches represent a significant shift from symptomatic management to potential curative strategies.

**Research Tools:**  
SGCA is used as a model to study membrane-cytoskeleton interactions and the pathophysiology of muscular dystrophies. Cell and animal models with SGCA mutations are employed to test novel therapeutics and understand disease mechanisms[5][12].

### Expert Opinions and Analysis

**Authoritative Perspectives:**  
Experts in neuromuscular disorders highlight the centrality of the DGC, and by extension SGCA, in maintaining muscle integrity. Disruption of this complex leads to a cascade of events culminating in muscle degeneration[1][3][11]. The field is moving toward precision medicine, with gene editing offering hope for previously untreatable genetic muscle diseases[5][12].

**Critical Challenges:**  
A major challenge is ensuring the safety and efficacy of gene-editing therapies, particularly with respect to off-target effects and long-term outcomes. Additionally, the heterogeneity of SGCA mutations complicates the development of universal therapies, necessitating personalized approaches[5][12].

### Relevant Statistics and Data from Recent Studies

- **Prevalence:** Limb-girdle muscular dystrophy type 2D is a rare disease, but exact prevalence rates are not well established due to underdiagnosis and genetic heterogeneity.
- **Therapeutic Progress:** Preclinical studies using base editing in human muscle stem cells have shown correction of SGCA mutations and partial restoration of protein function, though clinical efficacy remains to be demonstrated[5][12].
- **Mutation Spectrum:** Over 100 SGCA mutations have been reported, most leading to loss of protein function and severe clinical phenotypes[3][4].

### Summary Table: SGCA (Q16586) at a Glance

| Aspect                  | Details                                                                 |
|-------------------------|-------------------------------------------------------------------------|
| Gene Symbol             | SGCA                                                                   |
| Protein Name            | Alpha-sarcoglycan                                                      |
| UniProt ID              | Q16586                                                                 |
| Molecular Function      | Component of DGC; calcium ion binding; membrane-cytoskeleton linkage   |
| Biological Process      | Muscle development, regeneration, contraction                          |
| Cellular Localization   | Sarcolemma, membrane rafts, cell-cell junctions                        |
| Protein Domains         | Single-pass transmembrane, extracellular, cytoplasmic regions          |
| Key Interactions        | Biglycan, other sarcoglycans, dystrophin, syntrophins, dystroglycans   |
| Disease Association     | Limb-girdle muscular dystrophy type 2D (LGMDR3)                        |
| Therapeutic Approaches  | Gene editing (base editing, CRISPR/Cas9) in preclinical development    |

### URLs and Publication Dates

- **GeneCards**: Updated regularly, last accessed November 2025[1].
- **UniProt**: Entry last modified in 2023[11].
- **GlyCosmos**: Last updated August 4, 2025[10].
- **NCBI Gene**: Includes recent studies on base editing (2023–2024)[12].
- **Wikipedia**: Continuously updated, last substantive edit not specified[3].

### Conclusion

SGCA encodes alpha-sarcoglycan, a cornerstone of the dystrophin-glycoprotein complex essential for muscle membrane stability. Mutations in SGCA cause limb-girdle muscular dystrophy type 2D, a progressive and debilitating condition. Recent advances in gene editing offer promising therapeutic avenues, though significant challenges remain in translating these technologies to clinical practice. Ongoing research continues to elucidate the molecular intricacies of SGCA and its role in muscle biology, with the ultimate goal of developing effective treatments for sarcoglycanopathies[1][3][5].

## Citations

1. https://www.genecards.org/cgi-bin/carddisp.pl?gene=SGCA
2. https://patents.google.com/patent/US20230357754A1/en
3. https://en.wikipedia.org/wiki/SGCA
4. https://g2p.broadinstitute.org/gene/SGCA/protein/Q16586
5. https://glygen.org/protein/Q16586
6. https://flybase.org/reports/FBgn0032013
7. https://functionome.geneontology.org/gene/UniProtKB:Q16586
8. http://biogps.org/gene/6442/
9. https://marrvel.org/human/gene/6442
10. https://glycosmos.org/glycoproteins/Q16586
11. https://www.uniprot.org/uniprotkb/Q16586/entry
12. https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=6442
13. https://www.uniprot.org/uniprot/H0Y8T1_HUMAN